News Sentiment

LBRX sentiment intelligence

LB Pharmaceuticals Inc Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.95 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

-1.4% over one week, +15.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction -1.4% Price digesting
Trend fit Trend active 15.9% over four weeks
Fair value 42.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 30
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 6
TradingView 6
TradingKey 5
Investing.com 4
Moomoo 3
simplywall.st 3
Barron's 3

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 24
Analyst action 10
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
MarketBeat Direct company coverage

LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

LB Pharmaceuticals Inc (NASDAQ:LBRX) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 1-year price target of $39.50. The stock recently traded near its 52-week high at $32.95 and reported a better-than-expected quarterly loss. Several analysts

Tone
Positive 70/100
Event
Analyst action
Published
12 Jul 2026 18:40
Source
MarketBeat
Quiver Quantitative Direct company coverage

LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations

LB Pharmaceuticals Inc. has granted an equity award to Christopher Zergebel, its new Senior Vice President of Clinical Operations, consisting of an option to purchase 75,000 shares of common stock vesting over four years. This inducement grant aligns with Nasdaq Listing Rule 5635

Tone
Positive 74/100
Event
Market update
Published
10 Jul 2026 21:50
Source
Quiver Quantitative
Pluang Direct company coverage

LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule

LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, 75,000 stock options as an inducement equity award. This grant, under Nasdaq Listing Rule 5635(c)(4), aims to attract key talent, with options vesting over four years at an

Tone
Positive 63/100
Event
Market update
Published
10 Jul 2026 21:40
Source
Pluang
www.marketscreener.com Direct company coverage

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Inc. (Nasdaq: LBRX) announced an inducement grant of equity to Christopher Zergebel, their new Senior Vice President, Clinical Operations. Mr. Zergebel received an option to purchase 75,000 shares of common stock, vesting over four years, at an exercise price o

Tone
Positive 66/100
Event
Market update
Published
10 Jul 2026 20:40
Source
www.marketscreener.com
Moomoo Direct company coverage

Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals announced an inducement grant of 100,000 stock options to a new Vice President of Preclinical Development. The options, granted on July 10, 2026, have an exercise price of $2.49 per share, vest over four years, and were awarded outside of the company's 2024 Equ

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Moomoo
Moomoo Direct company coverage

Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45

Wolfe Research has initiated coverage on LB Pharmaceuticals (LBRX.US) with a Buy rating. The firm has set a price target of $45 for the company's shares. This initiation and target price suggest a positive outlook from Wolfe Research on LB Pharmaceuticals' future performance.

Tone
Positive 72/100
Event
Analyst action
Published
08 Jul 2026 05:40
Source
Moomoo
Investing.com Direct company coverage

Wolfe Research initiates LB Pharmaceuticals stock with outperform rating

Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a $45.00 price target. The firm is optimistic about LB-102, a next-generation antipsychotic in development, which has shown efficacy and a favorable safety profile in Phase

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 17:42
Source
Investing.com
Investing.com India Direct company coverage

Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com

Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a price target of $45.00, citing the potential of its drug LB-102 for schizophrenia and mood disorders. The company's stock has seen a significant return since its IPO in S

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 10:10
Source
Investing.com India
Finviz Direct company coverage

LBRX - LB Pharmaceuticals Inc Dividends

This article provides a detailed financial overview of LB Pharmaceuticals Inc (LBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also highlights key performance indicators such as EPS, insider/institutional ownership,

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 15:08
Source
Finviz
Sahm Direct company coverage

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of global development operations experience and will be instrumental in advancing the company's multiple clinical programs for LB-102, which inc

Tone
Positive 65/100
Event
Market update
Published
01 Jul 2026 19:12
Source
Sahm
Investing.com Nigeria Direct company coverage

LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com

LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, bringing over 25 years of global development operations experience. The company, which trades under NASDAQ:LBRX, is currently conducting Phase 3 and Phase 2 trials for neurop

Tone
Positive 68/100
Event
Market update
Published
01 Jul 2026 03:39
Source
Investing.com Nigeria
Insider Monkey Direct company coverage

5 Best Up and Coming Pharmaceutical Stocks to Buy Now

This article lists the top five up-and-coming pharmaceutical stocks, focusing on LB Pharmaceuticals Inc. (NASDAQ: LBRX), which is developing neuropsychiatric therapies. The company recently reported its Q1 2026 financial results, showing increased R&D and general administrative e

Tone
Positive 67/100
Event
Earnings
Published
30 Jun 2026 22:10
Source
Insider Monkey
Investing.com Direct company coverage

LB Pharmaceuticals names Christopher Zergebel as SVP

LB Pharmaceuticals Inc. (NASDAQ: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of experience to the biopharmaceutical company, which is advancing therapies for neuropsychiatric disorders, including a lead pro

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 13:09
Source
Investing.com
Stock Titan Direct company coverage

LB Pharmaceuticals taps veteran operator as 3 LB-102 trials advance

LB Pharmaceuticals (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, to bolster its leadership as it advances multiple clinical programs for its lead candidate, LB-102. Zergebel brings over 25 years of global development operations e

Tone
Positive 72/100
Event
Market update
Published
30 Jun 2026 12:09
Source
Stock Titan
TradingView Direct company coverage

Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX

The article focuses on the total assets of LB Pharmaceuticals Inc (NASDAQ: LBRX), noting that the market is closed with no trades. It provides a brief overview of the company's financial information, sourced from TradingView. The page primarily navigates through various sections

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:41
Source
TradingView
TradingView Direct company coverage

LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX)

This article provides an overview of LB Pharmaceuticals Inc. (NASDAQ: LBRX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, upcoming earnings reports, recent e

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

LBRX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings, earnings, revenue, and stock performance data. It highlights that 7 analysts offer a 1-year price forecast for LBRX, with a max estimate of $78.00 and a min estimate of

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
Simply Wall Street Direct company coverage

LB Pharmaceuticals (NasdaqGM:LBRX) Stock Forecast & Analyst Predictions

LB Pharmaceuticals's earnings are projected to decline by 25.7% per annum, while revenue is expected to grow by 79.8% annually, but the company is forecast to remain unprofitable for the next three years. The article also details recent company announcements, including the resign

Tone
Positive 65/100
Event
Earnings
Published
22 Jun 2026 13:10
Source
Simply Wall Street
Investing.com Direct company coverage

LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for LB Pharmaceuticals Inc (NASDAQ:LBRX), citing strong analyst support for its lead drug candidate, LB-102. Expert panels at a recent conference highlighted LB-102's potential for schizophrenia and depression

Tone
Positive 70/100
Event
Analyst action
Published
22 Jun 2026 12:40
Source
Investing.com
TradingKey Direct company coverage

LB Pharmaceuticals Inc (LBRX) Institutional Confidence

This article provides an overview of institutional confidence in LB Pharmaceuticals Inc (LBRX), detailing key institutional shareholders and their recent activity. It lists major holders like Deep Track Capital LP and RA Capital Management, LP, along with their shares held and pe

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings and EPS predictions. Based on 6 analysts, the current rating for LBRX is "Buy" with a target price indicating a 62.69% upside. The report also highlights past EPS performance a

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for LB Pharmaceuticals Inc (LBRX), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The company closed at $30.050, up 8.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of LB Pharmaceuticals Inc (LBRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock per

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for LB Pharmaceuticals Inc (LBRX), including business segments, regional revenue, and profit contribution. However, the data necessary for this analysis has not been disclosed by the company. Consequently, the a

Tone
Negative 40/100
Event
Earnings
Published
17 Jun 2026 09:39
Source
TradingKey
Stock Titan Direct company coverage

[8-K] LB PHARMACEUTICALS INC Reports Material Event

LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D., has resigned her officer role effective June 15, 2026, for personal reasons but will transition to an advisor position. She will provide full-time consulting services until September 15, 2026, while th

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 20:40
Source
Stock Titan